Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG:6990)
Hong Kong
· Delayed Price · Currency is HKD
305.00
-3.00 (-0.97%)
Last updated: Apr 2, 2025
HKG:6990 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
| FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Revenue | 1,933 | 1,540 | 803.93 | 32.32 |
| Revenue Growth (YoY) | 25.48% | 91.62% | 2387.26% | - |
| Cost of Revenue | 659.39 | 751.64 | 277.14 | 23.07 |
| Gross Profit | 1,274 | 788.85 | 526.8 | 9.25 |
| Selling, General & Admin | 346.03 | 199 | 93.03 | 90.98 |
| Research & Development | 1,206 | 1,031 | 845.98 | 727.67 |
| Other Operating Expenses | -66.39 | 12.59 | -18.27 | -14.16 |
| Operating Expenses | 1,486 | 1,243 | 920.75 | 804.49 |
| Operating Income | -212.12 | -453.7 | -393.95 | -795.24 |
| Interest Expense | -3.8 | -84.31 | -148.81 | -112.59 |
| Interest & Investment Income | 34.18 | 45.19 | 1.42 | 0.81 |
| Currency Exchange Gain (Loss) | 17.79 | 16.09 | -31.94 | 16.88 |
| EBT Excluding Unusual Items | -163.95 | -476.74 | -573.3 | -890.15 |
| Gain (Loss) on Sale of Investments | 21.55 | 10.53 | 0.51 | 0.36 |
| Gain (Loss) on Sale of Assets | -0.15 | -1.49 | 5.42 | -0.01 |
| Pretax Income | -142.55 | -467.69 | -567.36 | -889.8 |
| Income Tax Expense | 124.22 | 106.44 | 48.74 | - |
| Net Income | -266.77 | -574.13 | -616.1 | -889.8 |
| Preferred Dividends & Other Adjustments | - | -51.93 | -68 | -67.25 |
| Net Income to Common | -266.77 | -522.21 | -548.1 | -822.55 |
| Shares Outstanding (Basic) | 222 | 184 | 96 | 92 |
| Shares Outstanding (Diluted) | 222 | 184 | 96 | 92 |
| Shares Change (YoY) | 20.70% | 92.24% | 3.31% | - |
| EPS (Basic) | -1.20 | -2.84 | -5.74 | -8.90 |
| EPS (Diluted) | -1.20 | -2.84 | -5.74 | -8.90 |
| Free Cash Flow | -507.23 | -21.42 | -304.51 | -580.03 |
| Free Cash Flow Per Share | -2.29 | -0.12 | -3.19 | -6.27 |
| Gross Margin | 65.89% | 51.21% | 65.53% | 28.62% |
| Operating Margin | -10.97% | -29.45% | -49.00% | -2460.37% |
| Profit Margin | -13.80% | -33.90% | -68.18% | -2544.86% |
| Free Cash Flow Margin | -26.24% | -1.39% | -37.88% | -1794.52% |
| EBITDA | -178.2 | -419.78 | -367.99 | -775.61 |
| EBITDA Margin | -9.22% | -27.25% | -45.77% | - |
| D&A For EBITDA | 33.92 | 33.92 | 25.97 | 19.63 |
| EBIT | -212.12 | -453.7 | -393.95 | -795.24 |
| EBIT Margin | -10.97% | -29.45% | -49.00% | - |
Source: S&P Global Market Intelligence. Standard template.
Financial Sources.